Dr. Pereira’s presentation, titled “Plasma p-tau217 in Alzheimer Disease Dementia relates to Glucose Metabolism in Specific Brain Regions”, will describe the results of collaborative analyses conducted by ADMdx on April 5 in Vienna, Austria. This work evaluated the relationship between plasma p-tau 217, which is a marker associated with amyloid and tau pathology found in Alzheimer’s Disease, with effects upon brain function and volume as measured with brain imaging. Results showed that p-tau 217 levels are correlated with lower glucose metabolism (indicating reduced function) in brain regions typically affected in Alzheimer’s Disease. They also showed a relationship to the loss of brain volume in those regions. The image data provided insight to the extent and location of neuronal damage. The work demonstrates the way in which plasma biomarkers can be used in combination with imaging to provide a cohesive and informative view of patient status. Dr. Pereira, study PI, is assistant professor of neurology and neuroscience at the Icahn School of Medicine at Mount Sinai in New York.